Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. 1982

I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector

1 High pressure liquid chromatographic assays for the estimation of sulphinpyrazone and its sulphide, sulphone and p-hydroxy metabolites in plasma and urine are described. 2 Five normal volunteers received 200 mg and 400 mg sulphinpyrazone orally. Sulphinpyrazone was rapidly absorbed and eliminated with a half-life of approximately 4 h irrespective of dose. Peak plasma concentrations and area under the plasma concentration-time curves (AUC) were consistent with linear pharmacokinetic behaviour. 3 Plasma concentrations of the sulphone were low and peaked before those of the sulphide; its mean half-life was 3.1 h. The sulphide, which may be the sulphinpyrazone metabolite with activity on platelets, was eliminated with a mean half-life of 13.4 h. The AUC increases with dose of both metabolites suggested non-linearity. 4 Approximately 45-50% of the administered dose was eliminated in the urine as unchanged drug or as sulphone or p-hydroxy-sulphinpyrazone. The sulphide metabolite was not detected in the urine. The renal clearance of sulphinpyrazone was approximately 18 ml min-1 and that for the sulphone was similar. Sigma minus plots of the urinary excretion yielded half-lives of 3.5 h for the sulphone and 1 h for p-hydroxy-sulphinpyrazone.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D013440 Sulfides Chemical groups containing the covalent sulfur bonds -S-. The sulfur atom can be bound to inorganic or organic moieties. Sulfide,Thioether,Thioethers,Sulfur Ethers,Ethers, Sulfur

Related Publications

I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
January 1985, European journal of clinical pharmacology,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
April 1987, Cancer research,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
January 1996, European journal of clinical pharmacology,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
November 2012, Xenobiotica; the fate of foreign compounds in biological systems,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
November 1995, Biopharmaceutics & drug disposition,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
January 2021, European journal of drug metabolism and pharmacokinetics,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
January 2006, Clinical pharmacokinetics,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
April 2017, British journal of clinical pharmacology,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
August 2014, Journal of veterinary pharmacology and therapeutics,
I D Bradbrook, and V A John, and P J Morrison, and H J Rogers, and R G Spector
August 1991, Journal of clinical pharmacy and therapeutics,
Copied contents to your clipboard!